Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension

European Respiratory Journal

Volumn 46, Issue 2, 2015, Pages 405-413

  McLaughlin, Vallerie ^a   Channick, Richard N ^b   Ghofrani, Hossein Ardeschir ^c   Lemarié, Jean Christophe ^d   Naeije, Robert ^e   Packer, Milton ^f   Souza, Rogério ^g   Tapson, Victor F ^h   Tolson, Jonathan ⁱ   Al Hiti, Hikmet ^j   Meyer, Gisela ^k   Hoeper, Marius M ^l  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^d EFFI STAT   (France)

^e ERASME HOSPITAL   (Belgium)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ ACTELION PHARMACEUTICALS LTD   (Switzerland)

^j INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^k Santa Casa Complexo Hospitalar   (Brazil)

^l HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; PLACEBO; PROSTANOID; SILDENAFIL; ANTIHYPERTENSIVE AGENT; SULFONAMIDE; VASODILATOR AGENT;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HOSPITALIZATION; HUMAN; HYPOTENSION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; HYPERTENSION, PULMONARY; MIDDLE AGED; MULTICENTER STUDY; SWITZERLAND; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SILDENAFIL CITRATE; SULFONAMIDES; SWITZERLAND; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84938903925     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02044-2014     Document Type: Article

References (19)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
2. Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012; 21: 321-327.
3. Sitbon O, Simonneau G. Optimal management of severe pulmonary arterial hypertension. Eur Respir Rev 2011; 20: 254-261.
4. Ghofrani HA, Humbert M. The role of combination therapy in managing pulmonary arterial hypertension. Eur Respir Rev 2014; 23: 469-475.
5. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818.
6. Galiè N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 81S-88S.
7. Hoeper MM, Oudiz RJ, Peacock A, et al. Endpoints and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004; 43: 48S-55S.
8. Simonneau G, Galiè N, Jansa P, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol 2014; 172: 332-339.
9. Actelion Pharmaceuticals UK Ltd. Tracleer (bosentan) 62.5mg film-coated tablets. www.medicines.org.uk/emc/medicine/20422/SPC/Tracleer+(bosentan)+62%205mg+film-coated+tablets/ Date last accessed: September, 2014. Date last updated: January, 2015.
10. Channick RN, Simonneau G, Sitbon O, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
11. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
12. Galiè N, Rubin LJ, Hoeper MM, Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
13. Minai OA, Arroliga AC. Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan. South Med J 2006; 99: 880-883.
14. Hoeper MM, Faulenbach C, Golpon H, Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-1010.
15. EU Clinical Trials Register. EudraCT number: 2009-014490-41. www.clinicaltrialsregister.eu/ctr-search/trial/2009-014490-41/GB Date last accessed: September, 2014.
16. EU Clinical Trials Register. EudraCT number: 2009-011150-17. www.clinicaltrialsregister.eu/ctr-search/trial/2009-011150-17/GB Date last accessed: September, 2014.
17. Humbert M, Barst RJ, Robbins IM, Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
18. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
19. Paul GA, Gibbs JS, Boobis AR, Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005; 60: 107-112.